[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LT2006026A - Use of 2,5-dihidroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function - Google Patents

Use of 2,5-dihidroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function

Info

Publication number
LT2006026A
LT2006026A LT2006026A LT2006026A LT2006026A LT 2006026 A LT2006026 A LT 2006026A LT 2006026 A LT2006026 A LT 2006026A LT 2006026 A LT2006026 A LT 2006026A LT 2006026 A LT2006026 A LT 2006026A
Authority
LT
Lithuania
Prior art keywords
regulation
compounds
dihidroxybenzenesulfonic
impairment
treatment
Prior art date
Application number
LT2006026A
Other languages
Lithuanian (lt)
Other versions
LT5475B (en
Inventor
Jose Esteve-Soler
De Tejada-Gorman Inigo Saenz
Javier Angulo-Frutos
Original Assignee
Laboratorios Del Dr. Esteve, S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Del Dr. Esteve, S. A. filed Critical Laboratorios Del Dr. Esteve, S. A.
Priority to LT2006026A priority Critical patent/LT5475B/en
Publication of LT2006026A publication Critical patent/LT2006026A/en
Publication of LT5475B publication Critical patent/LT5475B/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to use of 2,5-dihydroxybenzenesulfonic compounds for the manufacture of a medicament for the regulation of nitric oxide (NO) synthesis and/or the regulation of EDHF (Endotelium-Derived-Hyperpolarizing factor) in the endothelium of diabetic patients, whereby the medicament is administered in a daily dose of the 2,5-dihydroxybenzenesulfonic compounds of formula (I) of less than 500 mg.
LT2006026A 2006-04-12 2006-04-12 Use of 2,5-dihidroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function LT5475B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LT2006026A LT5475B (en) 2006-04-12 2006-04-12 Use of 2,5-dihidroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LT2006026A LT5475B (en) 2006-04-12 2006-04-12 Use of 2,5-dihidroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function

Publications (2)

Publication Number Publication Date
LT2006026A true LT2006026A (en) 2007-10-25
LT5475B LT5475B (en) 2008-02-25

Family

ID=39027436

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2006026A LT5475B (en) 2006-04-12 2006-04-12 Use of 2,5-dihidroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function

Country Status (1)

Country Link
LT (1) LT5475B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204506A1 (en) 1972-05-17 1976-02-12 Esteve Labor Dr PROCEDURE FOR THE PREPARATION OF SALTS OF P-DIHYDROXYBENE DISULPHONIC ACIDS

Also Published As

Publication number Publication date
LT5475B (en) 2008-02-25

Similar Documents

Publication Publication Date Title
NZ589445A (en) Rasagiline for parkinson's disease modification
TW200719882A (en) Treatment of connective tissue diseases of the skin
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
MX2011013902A (en) Treatment of multiple sclerosis with laquinimod.
MX2009006742A (en) Novel compounds.
SG148177A1 (en) Novel cis-imidazolines
IL164291A0 (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
EA200870183A1 (en) LONG-TERM TREATMENT OF HIV INFECTION
BRPI0804623A2 (en) use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive impairment
UA85707C2 (en) Benzoxazines for treating respiratory tract diseases
DE69927497D1 (en) SULFONIC ACID OR SULFONYLAMINO-N- (HETEROARALKYL) -AZAHETEROZYKLYLAMIDE COMPOUNDS
MX2010003071A (en) Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain.
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
IL173822A0 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
LT2006026A (en) Use of 2,5-dihidroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function
NO20053032L (en) Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on a disturbance of NO production and / or regulation of EDHF function.
ATE416785T1 (en) THERAPEUTIC USES FOR C-PEPTIDE
LT2006025A (en) Use of 2,5-dihydroxybenzensulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function
MX2010006310A (en) O-desmethyl-venlafaxine for treating major depressive disorder.
BRPI0513549A (en) pharmaceutical compositions for the treatment of leishmaniasis
TW200626133A (en) Oral medication for twice-daily administration
MY138165A (en) Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20080412